A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus - Furie, R; Petri, M; Zamani, O (Arthritis Rheum, 2011)
et al.